Ziying Zhang

Ziying Zhang

Auto-generated profile, based on publicly available information

Ziying Zhang

Department of Radiation Oncology, The Affiliated Cancer Hospital of Xiangya School of Medicine Central South University/Hunan Cancer Hospital Changsha Hunan China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 October 2019 in Signal Transduction and Targeted Therapy
Verified
Journal Article
Open access
PDF file
ZZZiying Zhang
Ziying Zhang
HTHaosheng Tang
Haosheng Tang
PCPeng Chen
Peng Chen
HXHui Xie
Hui Xie
YTYongguang Tao
Yongguang Tao
The trillions of microorganisms in the gut microbiome have attracted much attention recently owing to their sophisticated and widespread impacts on numerous aspects of host pathophysiology. Remarkable progress in large-scale sequencing and mass spectrometry has increased our understanding of the influence of the microbiome and/or its metabolites on the onset and progression of extraintestinal cancers and the efficacy of cancer immunotherapy. Given the plasticity in microbial composition and function, microbial-based therapeutic interventions, including dietary modulation, prebiotics, and probiotics, as well as fecal microbial transplantation, potentially permit the development of novel strategies for cancer therapy to improve clinical outcomes. Herein, we summarize the latest evidence on the involvement of the gut microbiome in host immunity and metabolism, the effects of the microbiome on extraintestinal cancers and the immune response, and strategies to modulate the gut microbiome, and we discuss ongoing studies and future areas of research that deserve focused research efforts.

26 December 2019 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
ZZZiying Zhang
Ziying Zhang
PCPeng Chen
Peng Chen
HXHui Xie
Hui Xie
PCPeiguo Cao
Peiguo Cao
Purpose: A meta‐analysis was formulated to appraise the diagnostic accuracy of circulating tumor DNA (ctDNA) in hepatocellular carcinoma (HCC).Materials and Methods: We enrolled all relevant studies published until September 2019. Four primary subgroups were investigated: the subgroup of quantitative or qualitative analysis of ctDNA, the subgroup of Ras association domain family 1 isoform A (RASSF1A) methylation in ctDNA and the subgroup of the combined alpha‐fetoprotein (AFP) and ctDNA assay. We analyzed the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) as well as the area under the curve (AUC).Results: A total of 33 qualified articles with 4113 subjects were incorporated into our meta‐analysis. The combined SEN, SPE, and DOR in quantitative studies were 0.722 (95% confidence interval (95% CI): 0.686‐0.756), 0.823 (95% CI: 0.789‐0.854), 18.532 (95% CI: 8.245‐41.657), respectively, yielding an AUC of 0.880. For qualitative studies, the corresponding value was 0.568 (95% CI: 0.548‐0.587), 0.882 (95% CI: 0.867‐0.897), 10.457 (95% CI: 7.270‐15.040) and 0.787, respectively. Detection of RASSF1A methylation yielded an AUC of 0.841, with a SEN of 0.644 (95% CI: 0.608‐0.678) and a SPE of 0.875 (95% CI: 0.847‐0.900). AFP combined with ctDNA assay achieved an AUC of 0.944, with a SEN of 0.760 (95% CI: 0.728‐00.790) and a SPE of 0.920 (95% CI: 0.893‐00.942).Conclusion: Circulating tumor DNA displays a promising diagnostic potential in HCC. However, it is not independently sufficient and can serve as an assistant tool combined with AFP for HCC screening and detection.

7 October 2020 in Medical Science Monitor
Verified
Journal Article
Open access
PDF file
PCPeng Chen
Peng Chen
ZZZiying Zhang
Ziying Zhang
XCXiang Chen
Xiang Chen
BACKGROUND:Protein kinase membrane-associated tyrosine/threonine (PKMYT1) has been found in many tumors, but its association with clear cell renal cell carcinoma (ccRCC) remains unclear. MATERIAL AND METHODS:PKMYT1 expression in ccRCC was examined in the Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), and Tumor Immune Estimation Resource databases. The correlation between PKMYT1 expression and clinicopathological parameters was explored via the chi-square test. Receiver operating characteristic curves were used to estimate the diagnostic performance of PKMYT1. Kaplan-Meier curves, a Cox model, nomogram, time-dependent receiver operating characteristic curves, and decision curve analysis (DCA) were used to evaluate the prognostic value and clinical utility of PKMYT1. Genes coexpressed with PKMYT1 in ccRCC were identified based on TCGA, the gene expression profiling interactive, and cBioPortal. Gene Set Enrichment Analysis revealed biological pathways associated with PKMYT1 in ccRCC. RESULTS:Weighted gene coexpression network analysis identified PKMYT1 as one of the genes most significantly correlated with progression of histological grade. PKMYT1 was significantly upregulated in ccRCC compared with normal tissue (P<0.001), with a trend toward differentiating between individuals with ccRCC and those who were healthy (area under the curve=0.942). High PKMYT1 expression was correlated with unsatisfactory survival (hazard ratio=1.67, P=0.001), indicating that it is a risk factor for ccRCC. A nomogram incorporating PKMYT1 level was created and showed a clinical net benefit. PKMYT1 was strongly positively correlated with the anti-silencing function of 1B histone chaperone (ASF1B) gene in ccRCC. CONCLUSIONS:PKMYT1 is upregulated in ccRCC and its presence indicates poor prognosis, making it a potential therapeutic target for ccRCC.

17 January 2020 in Medical Science Monitor
Verified
Journal Article
Closed access
ZZZiying Zhang
Ziying Zhang
HXHui Xie
Hui Xie
PCPeng Chen
Peng Chen
PCPeiguo Cao
Peiguo Cao
Background: Primary clear cell carcinoma of the liver (PCCCL) is an infrequent variant of primary hepatocellular carcinoma (HCC), we retrospectively performed a large population-based cohort study to elucidate the relationships between demographic, carcinoma- and therapy-specific variables and overall survival (OS). Material/Methods: The Surveillance, Epidemiology and End Results (SEER) database was queried to extract data on 419 patients with pathologically confirmed PCCCL from 1988 to 2015. A nomogram with good accuracy was formulated to predict long-term survival of PCCCL patients. Results: The OS for PCCCL patients was 25.6 months (95% confidence interval [CI]: 22.2-29 months), the overall 1-year, 3-year, and 5-year survival rates were 59.5%, 39.3%, and 29.9%, respectively. Log-rank analysis revealed that there was no statistically significant discrepancy in clinical outcome between PCCCL and common-type HCC after propensity-matched analysis. Multivariate Cox analysis confirmed that larger lesions (>96 mm), distant metastases and elevated alpha-fetoprotein (AFP) levels were independent prognostic factors for undesirable outcome. Conversely, surgery was an independent protective factor (hazard ratio [HR]=0.23, 95% CI 0.17-0.31), which significantly boosted OS by virtually 35 months (47.3 months versus 12.7 months, P0.05). The nomogram incorporated 4 independent prognostic factors and its concordance index for predicting survival was 0.761. Conclusions: The prognosis of PCCCL resembled that of common-type HCC. Larger lesions, distant metastases, and enhanced AFP levels were associated with unsatisfactory prognosis. Surgery fulfill favorable prognosis while radiotherapy or chemotherapy exerted no significant effects on survival.

19 February 2021 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
QCQian Chai
Qian Chai
ZMZiang Meng
Ziang Meng
DLDexue Lu
Dexue Lu
ZZZiying Zhang
Ziying Zhang
MLMeili Liu
Meili Liu
WWWeihua Wu
Weihua Wu

24 March 2021 in Plastic and Reconstructive Surgery
Verified
Journal Article
Open access
ZZZiying Zhang
Ziying Zhang
CWChenglong Wang
Chenglong Wang
ZZZixuan Zhang
Zixuan Zhang
MXMinqiang Xin
Minqiang Xin